Endologix Value Stock - Dividend - Research Selection
Market price: 0,00 USD
Endologix Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-29.570.000|
|Free cash flow||-30.025.000|
|Liabilities & Shareholders equity||307.164.000|
|Diluted shares outstanding||16.863.800|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||337.276,00 USD|
|Raw Data Source|
Description of the company
Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company´s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company´s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.